Insiders · RNAZ

Erik Manting

Director at Transcode Therapeutics, Inc. (RNAZ)

Erik Manting has filed 4 insider reports with the SEC since June 2022, as director at Transcode Therapeutics, Inc. (RNAZ). The latest filing, on June 18, 2024, reports grant or award at Transcode Therapeutics, Inc. (RNAZ).

Filings
4
Companies
1
Bought on market
None
Sold on market
None

Companies where Erik Manting is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Transcode Therapeutics, Inc. logo
RNAZ
Transcode Therapeutics, Inc.
Director$1.30Jun 18, 2024

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Erik Manting with

Other insiders at the same companies

Questions about Erik Manting

What is Erik Manting's role at Transcode Therapeutics, Inc.?
Erik Manting reports to the SEC as director at Transcode Therapeutics, Inc. (RNAZ), according to the latest filing on June 18, 2024.
Has Erik Manting bought or sold stock recently?
No open-market purchases or sales by Erik Manting are on file. The filings report grant or award.
How do I get alerts when Erik Manting files?
Follow Erik Manting on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Erik Manting (SEC CIK 0001856180). Totals count each trade once, skipping amendments whose original is on file, from Jun 23, 2022 on. View on SEC EDGAR · Get this as JSON